Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79) - Image 1

£77.42

Springer Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79)

Name: Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79)
Brand: Springer
Price: 77.42 GBP
Availability: InStock

Oncology

This is the most expensive it has ever been. Walk away.

£77 today · previous high £77 · all-time low £77

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 90 days • 90 data points

Historical

Generating forecast...

Price Distribution

Price distribution over 90 days • 1 price levels

Days at Price

Price Analysis

Most common price: £77 (90 days, 100.0%)

Price range: £77 - £77

Price levels: 1 different prices over 90 days

Description

Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10]. Of the few drugs which are active in the advanced disease, only 5-fluorouracil (5-FU) and razoxane «±1,2-bis(3,4-dioxopiperazin-1-yl)propane) are suitable for long-term adjuvant treatment [2, 9]. 5-FU has been widely and intensively studied as adjuvant chemotherapy in CRC [7], but there is no unanimity that it has even the marginal influence on survival that has been claimed [3, 10]. Razoxane has not previously been tested for adjuvant or maintenance treatment in CRC. It has however a number of biological activities which might be thought useful in the treatment of residual or minimal tumours [1] and which might therefore make it useful as an adjuvant. Thus it specifically prevents tumour dissemination and metastases in some tumours and normalizes the neovasculature which the tumours induce [6, 8, 11]. The drug is not cytotoxic in the usual sense, does not affect non-dividing cells, and only blocks cell division during a brief period of the cell cycle in late G and/or early mitosis [12]. It does so non-selectively and most cells capable of 2 division examined so far have been affected by the drug. Even affected cells however are not destroyed immediately, but may increase in size and become multinucleate [5].

Product Specifications

Brand: Springer
Format: paperback
ASIN: 3642816835
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 21 December 2011
Listed Since: 12 July 2012

Barcode

No barcode data available

Springer Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79)

This is the most expensive it has ever been. Walk away.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Colorectal Cancer: Evidence-based Chemotherapy Strategies (Current Clinical Oncology)

Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results

Rectal Cancer: International Perspectives on Multimodality Management (Current Clinical Oncology)

Colorectal Cancer: Evidence-based Chemotherapy Strategies (Current Clinical Oncology)

Molecular Pathogenesis of Colorectal Cancer

Colorectal Cancer: Prevention, Diagnosis and Treatment

Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances: 42 (Cancer Treatment and Research, 42)

Colon Cancer Diagnosis and Therapy: Volume 2

Multidisciplinary Management of Rectal Cancer: Questions and Answers

Radiation Oncology Advances: 139 (Cancer Treatment and Research, 139)

Radiation Oncology Advances: 139 (Cancer Treatment and Research, 139)

Management of Colorectal Cancers in Older People

Cancer Chemotherapy 1: 7 (Cancer Treatment and Research)

Farnesyltransferase Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development)

Organ Directed Toxicities of Anticancer Drugs: Proceedings of the First International Symposium on the Organ Directed Toxicities of the Anticancer ... 4–6, 1987: 53 (Developments in Oncology, 53)

Early Gastrointestinal Cancers: 196 (Recent Results in Cancer Research, 196)

Early Gastrointestinal Cancers: 196 (Recent Results in Cancer Research, 196)

Non-coding RNAs in Colorectal Cancer: 937 (Advances in Experimental Medicine and Biology, 937)

Präoperative Radiochemotherapie bei lokal fortgeschrittenem Rektumkarzinom

Causes and Control of Colorectal Cancer: A Model for Cancer Prevention: 78 (Developments in Oncology, 78)

Supportive Care in Cancer Therapy: 13 (Cancer Treatment and Research, 13)

New Drugs, Concepts and Results in Cancer Chemotherapy: 58 (Cancer Treatment and Research, 58)

Immunotherapy for Gastrointestinal Cancer

Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment: 56 (Cancer Treatment and Research, 56)